Ranitidine injection is expected to be unavailable from the end of May, according to the DHSC. It … FDA has advised companies to recall their ranitidine if testing shows levels of NDMA above the acceptable daily intake (96 nanograms per day or 0.32 parts per million for ranitidine). Briefings published by PSNC covering topics such as opening hours, regulations, and NHS IT matters.Join our mailing list for a weekly round-up of news and resources, plus price concession/NCSO alerts.Our monthly updates on dispensing news and guidance, plus a variety of factsheets.Find out about locally commissioned community pharmacy services.This portal provides links to websites for all Local Pharmaceutical Committees (LPCs).Find out the latest on pharmacy funding and NHS statistics.Further to the previous ranitidine supply disruption alert (SDA/2019/005) issued on 15 October 2019, this is an update on the supply status of both ranitidine oral and injectable products.As investigations into ranitidine have progressed, the Medicines and Healthcare products Regulatory Agency (MHRA) have instructed suppliers of both oral and injectable ranitidine in the UK to quarantine all affected, unreleased stock at manufacturer level whilst their investigations are ongoing.Ranitidine tablets, effervescent tablets and oral solution are expected to be out of stock with no date for resupply until further notice.Ranitidine injection is now also expected to be out of stock imminently with no date for resupply until further notice.All oral formulations of Ranitidine are anticipated to be out of stock, with no date for resupply until further notice.Extremely limited supplies remaining in wholesalers and pharmacies, which have not been recalled by the MHRA, are available and can be supplied.No new patients should be initiated on treatment with ranitidine oral or injectable products.All patients should be reviewed as repeat prescriptions are requested and if ongoing treatment is required, be switched to clinical alternatives.Send enquiries about this notice to the DH Supply Resilience Team For more information on medicines shortages, click PSNC has agreed a position with NHS England and NHS Improvement (NHSE&I) and the Department of Health and Social Care...Contractors are reminded that as part of the further extension to the vaccine programme in 2020/21, people in the 50-64-year...Class 4 Medicines Defect Information: Zopiclone 3.75mg Tablets, Zopiclone 7.5mg Tablets (Ratiopharm Uk Limited) and Zopiclone 3.75mg Tablets (Generics Uk...NHS Digital is introducing an improved naming convention for pharmacy shared mailboxes. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued alerts to healthcare professionals and retailers that Perrigo Company is precautionarily recalling its ranitidine medicines.. OTC Concepts Ltd, Relconchem Ltd, Noumed Life Sciences and Medreich PLC recall The MHRA has issued an alert to healthcare professionals, as Teva UK Ltd is recalling all unexpired stock of certain batches of 2 types of Ranitidine medicines used to treat conditions such as heartburn and stomach ulcers.The 2 products affected are Ranitidine Effervescent Tablets 150 micrograms and 300 mg. Major manufacturers have undertaken a product recall, and new stock is not being released to the market. We’ll send you a link to a feedback form. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market FDA Advises Consumers, Patients and Health Care Professionals After New FDA Studies Show Risk to … The possible contamination of ranitidine with probable human carcinogen N-nitrosodimethylamine (NDMA) has promoted the recall. Since 2018 NDMA and similar compounds known as nitrosamines have been detected in a number of medicines, with EU regulators taking action … The MHRA has issued an alert to healthcare professionals, as Teva UK Ltd is recalling all unexpired stock of certain batches of 2 types of Ranitidine medicines used to treat conditions … “There’s a lot of concerns that, in our mind, justify completely recalling this product.”Ranitidine products are used to reduce the production of stomach acid in patients with conditions such as heartburn and stomach ulcers.All types of ranitidine are available on prescription in the UK, with the lowest strength tablets available for purchase.Elsewhere in the world ranitidine is widely available to buy over the counter.A spokesperson for the UK Medicines & Healthcare products Regulatory Agency (MHRA) said: “We are not aware of any specific information that would indicate that there is any risk to patients and we are not currently initiating any product recalls.“We are monitoring the issue, continue to liaise with our European counterparts, and will take appropriate action if necessary.”All rights reserved. Elsewhere in the world ranitidine is widely available to buy over the counter. The possible contamination of ranitidine with probable human carcinogen N-nitrosodimethylamine (NDMA) has promoted the recall. It will take only 2 minutes to fill in. All types of ranitidine are available on prescription in the UK, with the lowest strength tablets available for purchase. All remaining stock should be quarantined and returned without delay to the supplier.Patients should not stop taking their medication, and a treatment review is not necessary until the next routine appointment.The recall is a precautionary measure due to possible contamination of the active substance in Zantac, ranitidine, with an impurity called NDMA (N-nitrosodimethylamine) which has been identified as a risk factor in the development of certain cancers.The MHRA is actively involved with the European Medicines Agency (EMA) and other medicines regulators to determine the impact of what is an ongoing, global issue.